To install StudyMoose App tap and then “Add to Home Screen”
Save to my list
Remove from my list
In the competitive landscape of the analgesic market, strategic pricing plays a pivotal role in the success of a new product. Marvin Koslow, faced with the challenge of positioning Datril, must carefully consider the pricing strategy to maximize market penetration and profitability. This essay advocates for the adoption of a pricing strategy aligning Datril with Tylenol, leveraging the established brand reputation of Bristol-Myers. By positioning Datril as a gentle alternative to aspirin, specifically targeting Bufferin and Excedin users experiencing upset stomach, the product can tap into a niche market.
This recommendation addresses the initial failure of Datril in test markets and anticipates potential challenges, providing a robust and sustainable approach for long-term success.
Upon Datril's introduction to test markets, its failure to meet projected sales figures within the first month raised concerns. It is crucial to acknowledge that these projections might have been overly optimistic, given Tylenol's established presence with an 8% market share in the aspirin-dominated analgesic market.
Verified writer
Proficient in: Aspirin
4.7 (346)
“ This writer never make an mistake for me always deliver long before due date. Am telling you man this writer is absolutely the best. ”
Directly competing with Tylenol at the same price is unlikely to yield rapid market share gains within a short timeframe. Therefore, a more extended trial period, such as six months, would have allowed for a more accurate assessment of Datril's performance, aligning with the duration of committed marketing expenses. The initial success at a lower price may not accurately represent Datril's true long-term performance, necessitating a more patient and comprehensive evaluation.
Before delving into the details of the recommended strategy, it is essential to address the primary risk associated with positioning Datril as a cheaper alternative to Tylenol.
Competitor repositioning and defensive marketing strategies pose significant threats. McNeil Labs, the manufacturer of Tylenol, could swiftly respond by reducing the trade and selling prices of Tylenol to match Datril. This reactive measure may lead to public accusations of false advertising, potentially causing a reversal of initial gains and tarnishing the $6 million investment in marketing. Bristol-Myers would incur additional costs by pulling current advertisements and launching a new campaign.
Alternatively, McNeil Labs might choose an aggressive advertising approach for Tylenol, leveraging the support of its parent company, Johnson & Johnson. This shift could solidify Tylenol's market share, intensifying the competition for Datril. The swift execution of these strategies by Tylenol could impede Datril's market penetration. Additionally, based on Exhibit A, Datril would need to sell a significant number of bottles to break even, posing an efficiency challenge compared to Tylenol. Given Tylenol's 1974 sales quantity (as per Exhibit B), Datril's path to break-even quantities becomes even more uncertain, considering the highlighted risks.
Quality cannot serve as a key differentiator between Datril and Tylenol, as both products are virtually identical as pain relievers. To establish a strong market presence, the recommended strategy involves combining Bristol-Myers' well-established reputation with the recognized effectiveness of Bufferin and Excedin. The unique value proposition lies in positioning Datril as a gentle analgesic specifically tailored for individuals experiencing upset stomach, a common side effect of aspirin-based products. Bristol-Myers' significant consumer base for its aspirin products provides a competitive advantage, surpassing the user base of Tylenol.
Targeting Bristol-Myers' existing consumers, who may suffer from typical aspirin side effects, becomes the focal point of Datril's positioning and differentiation strategy. Communicating the value of eliminated side effects to this specific customer segment is essential. Cannibalization from Bufferin and Excedin, if it occurs, should not be perceived negatively. The recommended retail price of $2.85, double that of these aspirin products, ensures a profitable margin while catering to a distinct market segment seeking a gentler alternative.
In conclusion, the strategic pricing of Datril demands a nuanced approach to effectively compete in the analgesic market. By aligning Datril's pricing with Tylenol, leveraging Bristol-Myers' brand reputation, and positioning it as a gentle alternative for aspirin users with upset stomach, a unique market niche can be targeted. The initial failure in test markets can be attributed to overoptimistic projections and a need for a more extended evaluation period. Careful consideration of potential risks, including competitor responses, is essential. The recommended strategy focuses on Bristol-Myers' competitive advantage, its aspirin consumer base, and the distinct value proposition of Datril. Implementing this comprehensive approach will pave the way for Datril's success in a highly competitive market.
Strategic Pricing for Datril: A Comprehensive Analysis. (2017, Feb 09). Retrieved from https://studymoose.com/price-strategy-essay
👋 Hi! I’m your smart assistant Amy!
Don’t know where to start? Type your requirements and I’ll connect you to an academic expert within 3 minutes.
get help with your assignment
